Soleno Therapeutics
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has entered into a definitive agreement to acquire the company. The all-cash transaction, valued at approximately $2.9 billion, represents a significant premium